BACKGROUND: In May 2006, the UK Human Fertilization and Embryology Authority (HFEA) approved use of preimplantation genetic diagnosis (PGD) for lower penetrance, late onset cancer susceptibility syndromes such as hereditary breast and ovarian cancer (HBOC). This is the first report on views of BRCA gene mutation carriers on use of PGD for HBOC. METHODS: Between December 2005 and February 2006, a postal survey of BRCA mutation carriers attending a Familial Cancer Clinic was undertaken. RESULTS: Of 102 women sent questionnaires, 52 (51%) responded. Thirty-nine (75%) felt it was acceptable to offer PGD for HBOC. Fifteen (37.5%) of 40 who had completed their families would personally have considered PGD if it had been available. Only one of seven (14%) contemplating a future pregnancy would consider PGD. Eighteen (35%) wrote extensively about their concerns including increasing availability of effective treatment and good quality of life. CONCLUSIONS: The majority of BRCA gene mutation carriers are supportive of offering PGD to others, thus endorsing the HFEA decision. However, most women would not consider it personally. Concerns raised highlight the need for regular HFEA reviews of the licensing criteria, as HBOC may cease to be a "serious life threatening illness" in the future.
BACKGROUND: In May 2006, the UK Human Fertilization and Embryology Authority (HFEA) approved use of preimplantation genetic diagnosis (PGD) for lower penetrance, late onset cancer susceptibility syndromes such as hereditary breast and ovarian cancer (HBOC). This is the first report on views of BRCA gene mutation carriers on use of PGD for HBOC. METHODS: Between December 2005 and February 2006, a postal survey of BRCA mutation carriers attending a Familial Cancer Clinic was undertaken. RESULTS: Of 102 women sent questionnaires, 52 (51%) responded. Thirty-nine (75%) felt it was acceptable to offer PGD for HBOC. Fifteen (37.5%) of 40 who had completed their families would personally have considered PGD if it had been available. Only one of seven (14%) contemplating a future pregnancy would consider PGD. Eighteen (35%) wrote extensively about their concerns including increasing availability of effective treatment and good quality of life. CONCLUSIONS: The majority of BRCA gene mutation carriers are supportive of offering PGD to others, thus endorsing the HFEA decision. However, most women would not consider it personally. Concerns raised highlight the need for regular HFEA reviews of the licensing criteria, as HBOC may cease to be a "serious life threatening illness" in the future.
Authors: Ashley H Woodson; Kimberly I Muse; Heather Lin; Michelle Jackson; Danielle N Mattair; Leslie Schover; Terri Woodard; Laurie McKenzie; Richard L Theriault; Gabriel N Hortobágyi; Banu Arun; Susan K Peterson; Jessica Profato; Jennifer K Litton Journal: Oncologist Date: 2014-06-20
Authors: Marion Drüsedau; Jos C Dreesen; Inge Derks-Smeets; Edith Coonen; Ron van Golde; Jannie van Echten-Arends; Peter M M Kastrop; Marinus J Blok; Encarna Gómez-García; Joep P Geraedts; Hubert J Smeets; Christine E de Die-Smulders; Aimée D Paulussen Journal: Eur J Hum Genet Date: 2013-03-27 Impact factor: 4.246
Authors: Akriti Dewanwala; Anu Chittenden; Margery Rosenblatt; Rowena Mercado; Judy E Garber; Sapna Syngal; Elena M Stoffel Journal: Fam Cancer Date: 2011-09 Impact factor: 2.375